Regent Investment Management’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Regent Investment Management’s Portfolio PSTX Stock Details PSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-20,922	Closed	-$94K	–	212
2022 Q1	$94K	Sell	20,922 -4,078	-16%	-$18.4K	0.02%	209
2021 Q4	$170K	Hold	25,000	–	–	0.04%	216
2021 Q3	$182K	Hold	25,000	–	–	0.04%	210
2021 Q2	$251K	Buy	25,000 +2,000	+9%	+$17.9K	0.06%	189
2021 Q1	$220K	Buy	23,000 +3,000	+15%	+$29.4K	0.06%	191
2020 Q4	$219K	Buy	+20,000	New	+$211K	0.06%	179

Other funds holding PSTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Regent Investment Management's PSTX Position: Q2 2022 in Review

Regent Investment Management sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q2 2022, closing a stake of 20,922 shares — an estimated $94K sold.

Regent Investment Management first reported a position in PSTX in Q4 2020 and held it in 6 quarters. The position peaked at $251K in Q2 2021. 56 funds tracked by Wall St. Rank hold PSTX as of Q2 2022.

Regent Investment Management reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Regent Investment Management sold 20,922 Poseida Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $94K.
Regent Investment Management first reported a position in Poseida Therapeutics, Inc. Common Stock in Q4 2020 and held it in 6 quarters.
Regent Investment Management's Poseida Therapeutics, Inc. Common Stock position peaked at $251K in Q2 2021.
56 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Regent Investment Management's 13F filing for Q2 2022, filed 15 Jul 2022.